<p>RxSight（纳斯达克代码：RXST - 获取免费报告）在周四发布的研究报告中，摩根大通的研究分析师将其目标价格从 8.00 美元上调至 9.00 美元，Benzinga 报道。该券商目前对该股票的评级为 “减持”。摩根大通的目标价暗示该公司股价有 4.53% 的上涨潜力。</p>
<p>其他几位分析师最近也对 RXST 发布了报告。Zacks Research 在 9 月 8 日的报告中将 RxSight 的评级从 “强烈卖出” 上调至 “持有”。瑞银集团在 8 月 8 日的研究报告中将 RxSight 的目标价格从 16.00 美元下调至 8.00 美元，并对该股票给予 “中性” 评级。美国银行在 7 月 9 日的研究报告中将 RxSight 的目标价格从 18.00 美元下调至 9.00 美元，并给予该股票 “表现不佳” 的评级。派珀桑德勒在 7 月 9 日的研究报告中将 RxSight 的目标价格从 18.00 美元下调至 10.00 美元，并给予该股票 “中性” 评级。最后，Needham &amp; Company LLC 在周四的研究报告中将 RxSight 的目标价格从 11.00 美元上调至 12.00 美元，并给予该公司 “买入” 评级。一位分析师对该股票给予 “买入” 评级，九位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “减持”，共识目标价格为 9.56 美元。</p>
<p><strong>阅读我们关于 RXST 的最新研究报告</strong></p>
<h2>RxSight 价格表现</h2>
<p>周四中午交易时，纳斯达克 RXST 的股价上涨 0.27 美元，达到 8.61 美元。该公司的交易量为 1,770,506 股，而其平均交易量为 990,790 股。该股票的市值为 3.5232 亿美元，市盈率为-10.76，贝塔值为 1.16。RxSight 的 12 个月最低价为 6.32 美元，最高价为 55.57 美元。该公司的 50 日简单移动平均线为 8.79 美元，200 日简单移动平均线为 10.82 美元。</p>
<p>RxSight（纳斯达克代码：RXST - 获取免费报告）最近于 11 月 5 日公布了季度财报。该公司报告每股收益（EPS）为-0.04 美元，超出市场共识预期的-0.19 美元，超出幅度为 0.15 美元。该季度的营业收入为 3034 万美元，而市场共识预期为 2563 万美元。RxSight 的股本回报率为-11.56%，净利润率为-21.93%。该公司的收入同比下降 31.4%。去年同期，该公司每股收益为-0.16 美元。RxSight 已设定 2025 财年的每股收益指导。股票分析师预测 RxSight 今年的每股收益将为-0.7 美元。</p>
<h2>RxSight 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近调整了对该公司的持股。纽约梅隆银行在第一季度将其在 RxSight 的持股比例提高了 0.8%。纽约梅隆银行目前拥有 103,659 股该公司的股票，价值 2,617,000 美元，此前在上个季度又购买了 777 股。Petrus Trust Company LTA 在第一季度将其在 RxSight 的持股比例提高了 5.0%。Petrus Trust Company LTA 目前拥有 19,651 股该公司的股票，价值 496,000 美元，此前在上个季度又收购了 938 股。怀俄明州在第一季度将其在 RxSight 的持股比例提高了 91.5%。怀俄明州目前拥有 2,062 股该公司的股票，价值 52,000 美元，此前在上个季度又收购了 985 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 RxSight 的持股比例提高了 6.0%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前拥有 21,861 股该公司的股票，价值 552,000 美元，此前在上个季度又收购了 1,232 股。最后，Legal &amp; General Group Plc 在第二季度将其在 RxSight 的持股比例提高了 5.0%。Legal &amp; General Group Plc 目前拥有 44,574 股该公司的股票，价值 579,000 美元，此前在上个季度又收购了 2,121 股。机构投资者持有该公司 78.78% 的股票。</p>
<h2>关于 RxSight</h2>
<p>（获取免费报告）</p>
<p>RxSight, Inc 是一家商业阶段的医疗设备公司，专注于可调光眼内镜（LAL）的研究、开发、制造和销售，主要用于美国及国际上的白内障手术。它提供的 RxSight 系统使医生能够为白内障手术后的患者定制和增强视觉清晰度。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 RxSight 更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>3 只小型 AI 股票准备爆发（均低于 20 美元）</li>
<li>何时出售股票以获利或亏损</li>
<li>在下跌 16% 后，分析师关注 Meta Platforms 的重大复苏</li>
<li>上海证券交易所综合指数是什么？</li>
<li>思科的转折点？市场上被忽视的 AI 投资机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 RxSight 吗？</h2>
<p>在考虑 RxSight 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 RxSight 并不在名单上。</p>
<p>虽然 RxSight 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票的详情</p>

RXST

<p>摩根大通已将 RxSight（NASDAQ:RXST）的目标股价从 8.00 美元上调至 9.00 美元，维持 “减持” 评级。这表明与前一交易日收盘价相比，潜在上涨幅度为 4.53%。其他分析师的观点各异，Zacks 将评级上调至 “持有”，而瑞银则将目标价下调至 8.00 美元。RxSight 的股票交易价格为 8.61 美元，市值为 3.5232 亿美元。该公司报告的季度每股收益为（0.04 美元），超出预期，但收入同比下降 31.4%。机构投资者持有 78.78% 的股份</p>

<p>RxSight (NASDAQ:RXST - Get Free Report) had its price objective raised by research analysts at JPMorgan Chase &amp; Co. from $8.00 to $9.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an &#34;underweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s price target would suggest a potential upside of 4.53% from the company's previous close.</p>
<div class="lb-trans"><p>RxSight（纳斯达克代码：RXST - 获取免费报告）在周四发布的研究报告中，摩根大通的研究分析师将其目标价格从 8.00 美元上调至 9.00 美元，Benzinga 报道。该券商目前对该股票的评级为 “减持”。摩根大通的目标价暗示该公司股价有 4.53% 的上涨潜力。</p>
</div><p>Several other analysts also recently issued reports on RXST. Zacks Research raised RxSight from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, September 8th. UBS Group cut their target price on RxSight from $16.00 to $8.00 and set a &#34;neutral&#34; rating on the stock in a research note on Friday, August 8th. Bank of America cut their target price on RxSight from $18.00 to $9.00 and set an &#34;underperform&#34; rating on the stock in a research note on Wednesday, July 9th. Piper Sandler cut their target price on RxSight from $18.00 to $10.00 and set a &#34;neutral&#34; rating on the stock in a research note on Wednesday, July 9th. Finally, Needham &amp; Company LLC lifted their target price on RxSight from $11.00 to $12.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Reduce&#34; and a consensus price target of $9.56.</p>
<div class="lb-trans"><p>其他几位分析师最近也对 RXST 发布了报告。Zacks Research 在 9 月 8 日的报告中将 RxSight 的评级从 “强烈卖出” 上调至 “持有”。瑞银集团在 8 月 8 日的研究报告中将 RxSight 的目标价格从 16.00 美元下调至 8.00 美元，并对该股票给予 “中性” 评级。美国银行在 7 月 9 日的研究报告中将 RxSight 的目标价格从 18.00 美元下调至 9.00 美元，并给予该股票 “表现不佳” 的评级。派珀桑德勒在 7 月 9 日的研究报告中将 RxSight 的目标价格从 18.00 美元下调至 10.00 美元，并给予该股票 “中性” 评级。最后，Needham &amp; Company LLC 在周四的研究报告中将 RxSight 的目标价格从 11.00 美元上调至 12.00 美元，并给予该公司 “买入” 评级。一位分析师对该股票给予 “买入” 评级，九位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “减持”，共识目标价格为 9.56 美元。</p>
</div><p><strong>Read Our Latest Research Report on RXST</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 RXST 的最新研究报告</strong></p>
</div><h2>RxSight Price Performance</h2>
<div class="lb-trans"><h2>RxSight 价格表现</h2>
</div><p>Shares of NASDAQ RXST traded up $0.27 during mid-day trading on Thursday, hitting $8.61. The company had a trading volume of 1,770,506 shares, compared to its average volume of 990,790. The stock has a market cap of $352.32 million, a price-to-earnings ratio of -10.76 and a beta of 1.16. RxSight has a 12 month low of $6.32 and a 12 month high of $55.57. The firm's 50 day simple moving average is $8.79 and its two-hundred day simple moving average is $10.82.</p>
<div class="lb-trans"><p>周四中午交易时，纳斯达克 RXST 的股价上涨 0.27 美元，达到 8.61 美元。该公司的交易量为 1,770,506 股，而其平均交易量为 990,790 股。该股票的市值为 3.5232 亿美元，市盈率为-10.76，贝塔值为 1.16。RxSight 的 12 个月最低价为 6.32 美元，最高价为 55.57 美元。该公司的 50 日简单移动平均线为 8.79 美元，200 日简单移动平均线为 10.82 美元。</p>
</div><p>RxSight (NASDAQ:RXST - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.15. The business had revenue of $30.34 million for the quarter, compared to the consensus estimate of $25.63 million. RxSight had a negative return on equity of 11.56% and a negative net margin of 21.93%.The business's revenue was down 31.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.16) EPS. RxSight has set its FY 2025 guidance at EPS. Equities analysts forecast that RxSight will post -0.7 earnings per share for the current year.</p>
<div class="lb-trans"><p>RxSight（纳斯达克代码：RXST - 获取免费报告）最近于 11 月 5 日公布了季度财报。该公司报告每股收益（EPS）为-0.04 美元，超出市场共识预期的-0.19 美元，超出幅度为 0.15 美元。该季度的营业收入为 3034 万美元，而市场共识预期为 2563 万美元。RxSight 的股本回报率为-11.56%，净利润率为-21.93%。该公司的收入同比下降 31.4%。去年同期，该公司每股收益为-0.16 美元。RxSight 已设定 2025 财年的每股收益指导。股票分析师预测 RxSight 今年的每股收益将为-0.7 美元。</p>
</div><h2>Institutional Trading of RxSight</h2>
<div class="lb-trans"><h2>RxSight 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its stake in shares of RxSight by 0.8% in the 1st quarter. Bank of New York Mellon Corp now owns 103,659 shares of the company's stock worth $2,617,000 after buying an additional 777 shares in the last quarter. Petrus Trust Company LTA grew its holdings in shares of RxSight by 5.0% in the 1st quarter. Petrus Trust Company LTA now owns 19,651 shares of the company's stock worth $496,000 after acquiring an additional 938 shares during the last quarter. State of Wyoming grew its holdings in shares of RxSight by 91.5% in the 1st quarter. State of Wyoming now owns 2,062 shares of the company's stock worth $52,000 after acquiring an additional 985 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of RxSight by 6.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,861 shares of the company's stock worth $552,000 after acquiring an additional 1,232 shares during the last quarter. Finally, Legal &amp; General Group Plc grew its holdings in shares of RxSight by 5.0% in the 2nd quarter. Legal &amp; General Group Plc now owns 44,574 shares of the company's stock worth $579,000 after acquiring an additional 2,121 shares during the last quarter. Institutional investors own 78.78% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近调整了对该公司的持股。纽约梅隆银行在第一季度将其在 RxSight 的持股比例提高了 0.8%。纽约梅隆银行目前拥有 103,659 股该公司的股票，价值 2,617,000 美元，此前在上个季度又购买了 777 股。Petrus Trust Company LTA 在第一季度将其在 RxSight 的持股比例提高了 5.0%。Petrus Trust Company LTA 目前拥有 19,651 股该公司的股票，价值 496,000 美元，此前在上个季度又收购了 938 股。怀俄明州在第一季度将其在 RxSight 的持股比例提高了 91.5%。怀俄明州目前拥有 2,062 股该公司的股票，价值 52,000 美元，此前在上个季度又收购了 985 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 RxSight 的持股比例提高了 6.0%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前拥有 21,861 股该公司的股票，价值 552,000 美元，此前在上个季度又收购了 1,232 股。最后，Legal &amp; General Group Plc 在第二季度将其在 RxSight 的持股比例提高了 5.0%。Legal &amp; General Group Plc 目前拥有 44,574 股该公司的股票，价值 579,000 美元，此前在上个季度又收购了 2,121 股。机构投资者持有该公司 78.78% 的股票。</p>
</div><h2>About RxSight</h2>
<div class="lb-trans"><h2>关于 RxSight</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.</p>
<div class="lb-trans"><p>RxSight, Inc 是一家商业阶段的医疗设备公司，专注于可调光眼内镜（LAL）的研究、开发、制造和销售，主要用于美国及国际上的白内障手术。它提供的 RxSight 系统使医生能够为白内障手术后的患者定制和增强视觉清晰度。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than RxSight</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>3 Small AI Stocks Ready to Explode (All Under $20)</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Cisco's Turning Point? The Market's Most Overlooked AI Play</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 RxSight 更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>3 只小型 AI 股票准备爆发（均低于 20 美元）</li>
<li>何时出售股票以获利或亏损</li>
<li>在下跌 16% 后，分析师关注 Meta Platforms 的重大复苏</li>
<li>上海证券交易所综合指数是什么？</li>
<li>思科的转折点？市场上被忽视的 AI 投资机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=RXST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in RxSight Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 RxSight 吗？</h2>
</div><p>Before you consider RxSight, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 RxSight 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 RxSight 并不在名单上。</p>
</div><p>While RxSight currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 RxSight 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票的详情</p>
</div>

摩根大通对 RxSight（NASDAQ:RXST）股票价格发布了乐观的预测